1. Home
  2. NREF vs LXEO Comparison

NREF vs LXEO Comparison

Compare NREF & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NexPoint Real Estate Finance Inc.

NREF

NexPoint Real Estate Finance Inc.

SELL

Current Price

$11.24

Market Cap

298.0M

Sector

Real Estate

ML Signal

SELL

Logo Lexeo Therapeutics Inc.

LXEO

Lexeo Therapeutics Inc.

SELL

Current Price

$3.22

Market Cap

348.7M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
NREF
LXEO
Founded
2019
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
298.0M
348.7M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
NREF
LXEO
Price
$11.24
$3.22
Analyst Decision
Hold
Strong Buy
Analyst Count
3
9
Target Price
$14.50
★ $20.67
AVG Volume (30 Days)
66.3K
★ 1.1M
Earning Date
11-05-2026
11-16-2026
Dividend Yield
★ 16.30%
N/A
EPS Growth
N/A
★ 39.81
EPS
★ N/A
N/A
Revenue
N/A
★ $654,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.05
N/A
P/E Ratio
$4.78
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.16
$2.55
52 Week High
$18.43
$10.99

Technical Indicators

Market Signals
Indicator
NREF
LXEO
Relative Strength Index (RSI) 20.74 54.64
Support Level N/A $2.72
Resistance Level $16.04 $3.56
Average True Range (ATR) 0.68 0.38
MACD -0.27 0.05
Stochastic Oscillator 2.47 36.56

Price Performance

Historical Comparison
NREF
LXEO

About NREF NexPoint Real Estate Finance Inc.

NexPoint Real Estate Finance Inc is a commercial mortgage REIT focused on generating attractive, risk-adjusted returns for shareholders over the long term. The company invests mainly in first-lien mortgage loans, mezzanine loans, preferred equity, multifamily properties, and common equity investments, as well as multifamily and single-family rental CMBS securitizations, promissory notes, revolving credit facilities, and stock warrants. It focuses on real estate sectors where its management has operating expertise, including multifamily, single-family rental, self-storage, industrial, and life sciences, mainly in top metropolitan areas.

About LXEO Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Share on Social Networks: